Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines

Fig. 2

Impact of the annual HZ/su waning rate starting 4 years following vaccination on the threshold vaccine cost per series when using a a time horizon of 15 years or b a lifetime time horizon. The cost-effectiveness threshold was set at €20,000 per quality-adjusted life year gained. HZ, herpes zoster; HZ/su, herpes zoster subunit vaccine; VE, vaccine efficacy

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us